CP and COVID-19: It is also of significance to identify the optimal dose of CP that contains high-level neutralizing antibodies which are adequate to trigger anti-viral immune responses and mitigate viremia.110 Currently, a large number of studies are underway to clinically assess the use of CP as a therapeutic for COVID-19, and there are approximately 25 trials are in phase III or IV and are anticipated to conclude soon (Table 2).